Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review.
Adolescent
Adult
Aftercare
/ methods
Cancer Survivors
/ psychology
Child
Depression
/ psychology
Drug-Related Side Effects and Adverse Reactions
/ complications
Exercise
/ physiology
Female
Humans
Life Style
Male
Neoplasms
/ complications
Nutrition Assessment
Preventive Medicine
/ methods
Risk Factors
Surveys and Questionnaires
Time Factors
Young Adult
AYA
CAYA
Children adolescents and young adults after cancer
Follow-up care
Lifestyle intervention
Long-term side effects
Long-term toxicity
Prevention programme
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Jan 2020
06 Jan 2020
Historique:
received:
25
03
2019
accepted:
23
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
17
6
2020
Statut:
epublish
Résumé
Improved, multimodal treatment strategies have been shown to increase cure rates in cancer patients. Those who survive cancer as a child, adolescent or young adult (CAYA), are at a higher risk for therapy-, or disease-related, late or long-term effects. The CARE for CAYA-Program has been developed to comprehensively assess any potential future problems, to offer need-based preventative interventions and thus to improve long-term outcomes in this particularly vulnerable population. The trial is designed as an adaptive trial with an annual comprehensive assessment followed by needs stratified, modular interventions, currently including physical activity, nutrition and psycho-oncology, all aimed at improving the lifestyle and/or the psychosocial situation of the patients. Patients, aged 15-39 years old, with a prior cancer diagnosis, who have completed tumour therapy and are in follow-up care, and who are tumour free, will be included. At baseline (and subsequently on an annual basis) the current medical and psychosocial situation and lifestyle of the participants will be assessed using a survey compiled of various validated questionnaires (e.g. EORTC QLQ C30, NCCN distress thermometer, PHQ-4, BSA, nutrition protocol) and objective parameters (e.g. BMI, WHR, co-morbidities like hyperlipidaemia, hypertension, diabetes), followed by basic care (psychological and lifestyle consultation). Depending on their needs, CAYAs will be allocated to preventative interventions in the above-mentioned modules over a 12-month period. After 1 year, the assessment will be repeated, and further interventions may be applied as needed. During the initial trial phase, the efficacy of this approach will be compared to standard care (waiting list with intervention in the following year) in a randomized study. During this phase, 530 CAYAs will be included and 320 eligible CAYAs who are willing to participate in the interventions will be randomly allocated to an intervention. Overall, 1500 CAYAs will be included and assessed. The programme is financed by the innovation fund of the German Federal Joint Committee and will be conducted at 14 German sites. Recruitment began in January 2018. CAYAs are at high risk for long-term sequelae. Providing structured interventions to improve lifestyle and psychological situation may counteract against these risk factors. The programme serves to establish uniform regular comprehensive assessments and need-based interventions to improve long-term outcome in CAYA survivors. Registered at the German Clinical Trial Register (ID: DRKS00012504, registration date: 19th January 2018).
Sections du résumé
BACKGROUND
BACKGROUND
Improved, multimodal treatment strategies have been shown to increase cure rates in cancer patients. Those who survive cancer as a child, adolescent or young adult (CAYA), are at a higher risk for therapy-, or disease-related, late or long-term effects. The CARE for CAYA-Program has been developed to comprehensively assess any potential future problems, to offer need-based preventative interventions and thus to improve long-term outcomes in this particularly vulnerable population.
METHODS
METHODS
The trial is designed as an adaptive trial with an annual comprehensive assessment followed by needs stratified, modular interventions, currently including physical activity, nutrition and psycho-oncology, all aimed at improving the lifestyle and/or the psychosocial situation of the patients. Patients, aged 15-39 years old, with a prior cancer diagnosis, who have completed tumour therapy and are in follow-up care, and who are tumour free, will be included. At baseline (and subsequently on an annual basis) the current medical and psychosocial situation and lifestyle of the participants will be assessed using a survey compiled of various validated questionnaires (e.g. EORTC QLQ C30, NCCN distress thermometer, PHQ-4, BSA, nutrition protocol) and objective parameters (e.g. BMI, WHR, co-morbidities like hyperlipidaemia, hypertension, diabetes), followed by basic care (psychological and lifestyle consultation). Depending on their needs, CAYAs will be allocated to preventative interventions in the above-mentioned modules over a 12-month period. After 1 year, the assessment will be repeated, and further interventions may be applied as needed. During the initial trial phase, the efficacy of this approach will be compared to standard care (waiting list with intervention in the following year) in a randomized study. During this phase, 530 CAYAs will be included and 320 eligible CAYAs who are willing to participate in the interventions will be randomly allocated to an intervention. Overall, 1500 CAYAs will be included and assessed. The programme is financed by the innovation fund of the German Federal Joint Committee and will be conducted at 14 German sites. Recruitment began in January 2018.
DISCUSSION
CONCLUSIONS
CAYAs are at high risk for long-term sequelae. Providing structured interventions to improve lifestyle and psychological situation may counteract against these risk factors. The programme serves to establish uniform regular comprehensive assessments and need-based interventions to improve long-term outcome in CAYA survivors.
TRIAL REGISTRATION
BACKGROUND
Registered at the German Clinical Trial Register (ID: DRKS00012504, registration date: 19th January 2018).
Identifiants
pubmed: 31906955
doi: 10.1186/s12885-019-6492-5
pii: 10.1186/s12885-019-6492-5
pmc: PMC6945396
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Subventions
Organisme : innovation fund of the German Federal Joint Committee (GBA)
ID : -
Références
Open Obes J. 2011;3:87-97
pubmed: 22238561
Patient Educ Couns. 2016 Jul;99(7):1099-1105
pubmed: 26879805
Cancer. 2018 Mar 1;124(5):1036-1043
pubmed: 29205290
Patient Educ Couns. 2013 Aug;92(2):266-72
pubmed: 23647980
N Engl J Med. 1991 Mar 21;324(12):808-15
pubmed: 1997853
J Pediatr Oncol Nurs. 2007 Sep-Oct;24(5):264-73
pubmed: 17827492
PLoS Med. 2017 May 9;14(5):e1002296
pubmed: 28486495
Support Care Cancer. 2009 Aug;17(8):1041-8
pubmed: 19015892
J Clin Endocrinol Metab. 2003 Jun;88(6):2586-92
pubmed: 12788859
Eur J Pediatr. 2015 Jun;174(6):791-9
pubmed: 25428233
Addict Behav. 1982;7(2):133-42
pubmed: 7102444
Pediatr Blood Cancer. 2016 Sep;63(9):1629-35
pubmed: 27198652
Support Care Cancer. 2015 Feb;23(2):501-10
pubmed: 25294658
ESMO Open. 2017 Sep 8;2(4):e000252
pubmed: 29018578
J Clin Endocrinol Metab. 2012 Oct;97(10):3584-92
pubmed: 22865901
J Pediatr Hematol Oncol. 2008 Apr;30(4):272-80
pubmed: 18391695
Pediatr Blood Cancer. 2018 Aug;65(8):e27216
pubmed: 29722481
CA Cancer J Clin. 2004 Jul-Aug;54(4):208-36
pubmed: 15253918
Lancet. 2000 Sep 16;356(9234):993-7
pubmed: 11041401
Pediatr Blood Cancer. 2016 Jul;63(7):1254-63
pubmed: 26999299
Psychooncology. 2014 Oct;23(10):1196-9
pubmed: 24639118
Br J Psychiatry Suppl. 2000;(39):s28-33
pubmed: 10945075
Cancer Manag Res. 2015 Jun 01;7:121-31
pubmed: 26064068
Psychooncology. 2012 Aug;21(8):827-35
pubmed: 21484938
J Clin Oncol. 2015 Aug 10;33(23):2545-52
pubmed: 26150441
BMJ. 2009 Dec 08;339:b4606
pubmed: 19996459
Biometrics. 1991 Jun;47(2):511-21
pubmed: 1912258
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Nat Rev Cancer. 2014 Jan;14(1):61-70
pubmed: 24304873
J Acad Nutr Diet. 2013 Apr;113(4):569-80
pubmed: 23415502
Arch Intern Med. 2009 Aug 10;169(15):1381-8
pubmed: 19667301
J Cancer Surviv. 2016 Aug;10(4):743-58
pubmed: 26897613
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
J Clin Oncol. 2017 May 20;35(15):1704-1712
pubmed: 28355116
Pediatr Blood Cancer. 2012 Jun;58(6):959-63
pubmed: 22431246
BMJ. 2010 Apr 27;340:c1900
pubmed: 20423957
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Cancer. 2005 Oct 15;104(8):1751-60
pubmed: 16130127
Pediatr Blood Cancer. 2017 Feb;64(2):387-394
pubmed: 27615711
Cancer. 2011 May 15;117(10 Suppl):2289-94
pubmed: 21523748
J Clin Oncol. 2009 May 10;27(14):2339-55
pubmed: 19364955
JAMA Oncol. 2018 Oct 1;4(10):1352-1358
pubmed: 29862412
J Cancer Surviv. 2013 Sep;7(3):355-68
pubmed: 23532799
Lancet Child Adolesc Health. 2018 May;2(5):371-378
pubmed: 30169270
Biol Blood Marrow Transplant. 2015 Jul;21(7):1278-83
pubmed: 25865649
J Cancer Surviv. 2007 Dec;1(4):261-74
pubmed: 18648961
J Cancer Surviv. 2012 Dec;6(4):441-50
pubmed: 22956304
J Clin Oncol. 2012 May 1;30(13):1429-37
pubmed: 22473161
J Pediatr Psychol. 2012 Jul;37(6):634-46
pubmed: 22427699
Eur J Cancer. 2003 Dec;39(18):2584-99
pubmed: 14642921
J Affect Disord. 2010 Apr;122(1-2):86-95
pubmed: 19616305
J Affect Disord. 2015 Jul 15;180:21-8
pubmed: 25879721
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1114-24
pubmed: 27197285
PLoS One. 2018 Aug 9;13(8):e0201449
pubmed: 30092052
J Clin Oncol. 2018 Jul 20;36(21):2153-2159
pubmed: 29874130
Cancer. 2016 Sep 1;122(17):2747-56
pubmed: 27258389
Psychother Psychosom Med Psychol. 1989 Jul;39(7):248-55
pubmed: 2762479
Cancer. 2019 Jan 1;125(1):144-152
pubmed: 30368771
J Clin Oncol. 2014 Nov 10;32(32):3643-50
pubmed: 25311213
Nat Rev Endocrinol. 2016 Jun;12(6):319-36
pubmed: 27032982
J Adolesc Young Adult Oncol. 2011 Dec;1(4):188-194
pubmed: 23610737
Pediatr Blood Cancer. 2015 Aug;62(8):1461-7
pubmed: 25808589
J Natl Cancer Inst. 1998 Feb 4;90(3):219-25
pubmed: 9462679
Oncol Nurs Forum. 2007 May;34(3):643-51
pubmed: 17573323
Ann Behav Med. 2011 Aug;42(1):91-8
pubmed: 21328040
Pediatr Blood Cancer. 2014 May;61(5):885-93
pubmed: 24395288
Integr Cancer Ther. 2014 Mar;13(2):121-32
pubmed: 24105359
Pediatr Blood Cancer. 2015 Nov;62(11):2058-9
pubmed: 26152397
Patient Educ Couns. 2015 Feb;98(2):199-206
pubmed: 25468398
J Clin Oncol. 2017 Oct 20;35(30):3474-3481
pubmed: 28817372
Med Pediatr Oncol. 1992;20(4):301-6
pubmed: 1608351
BMC Cancer. 2016 Nov 8;16(1):872
pubmed: 27825320
J Cancer Educ. 2014 Mar;29(1):91-8
pubmed: 24078346
J Clin Oncol. 2012 Jul 1;30(19):2393-400
pubmed: 22614977
Semin Oncol Nurs. 2008 Aug;24(3):153-63
pubmed: 18687261